Baricitinib as the treatment of choice for hospitalised individuals with COVID-19.
作者信息
Richardson Peter J, Stebbing Justin
机构信息
Benevolent AI, Maple Street, London.
Department of Surgery and Cancer, Imperial College, London.
出版信息
EClinicalMedicine. 2022 Jul;49:101493. doi: 10.1016/j.eclinm.2022.101493. Epub 2022 Jun 3.
Abstract
摘要
相似文献
1
Baricitinib as the treatment of choice for hospitalised individuals with COVID-19.巴瑞替尼作为新冠肺炎住院患者的治疗选择。
EClinicalMedicine. 2022 Jul;49:101493. doi: 10.1016/j.eclinm.2022.101493. Epub 2022 Jun 3.
2
Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19.阿那白滞素与巴瑞替尼：COVID-19住院患者的不同治疗策略
J Clin Med. 2021 Sep 6;10(17):4019. doi: 10.3390/jcm10174019.
3
Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.对于因 COVID-19 住院并接受地塞米松治疗的患者，托珠单抗或巴瑞替尼的起始治疗与相似的临床结果相关。
Front Pharmacol. 2022 May 30;13:866441. doi: 10.3389/fphar.2022.866441. eCollection 2022.
4
Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA.在美国，对于因新冠肺炎住院的患者，巴瑞替尼+标准治疗方案比标准治疗方案更具成本效益。
PharmacoEcon Outcomes News. 2021;891(1):3. doi: 10.1007/s40274-021-08161-9. Epub 2021 Nov 13.
5
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA.在美国，对于住院的新冠患者，巴瑞替尼联合瑞德西韦相较于单用瑞德西韦可节省成本。
PharmacoEcon Outcomes News. 2021;892(1):3. doi: 10.1007/s40274-021-08198-6. Epub 2021 Nov 27.
6
Additional baricitinib loading dose improves clinical outcome in COVID-19.额外的巴瑞替尼负荷剂量可改善新冠病毒病的临床结局。
Open Med (Wars). 2020 Dec 5;16(1):41-46. doi: 10.1515/med-2021-0010. eCollection 2021.
7
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.巴瑞替尼治疗新型冠状病毒肺炎的人工智能辅助识别及临床疗效
Vaccines (Basel). 2022 Jun 15;10(6):951. doi: 10.3390/vaccines10060951.
8
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.巴瑞替尼：关于COVID-19的药理学、安全性及新出现临床经验的综述
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
9
A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.关于巴瑞替尼同情用药治疗一名患有严重新冠病毒感染症状儿科患者的新报告。
J Med Cases. 2021 Mar;12(3):94-98. doi: 10.14740/jmc3629. Epub 2021 Jan 19.
10
Current Status of Baricitinib as a Repurposed Therapy for COVID-19.巴瑞替尼作为新冠病毒病重新利用疗法的现状
Pharmaceuticals (Basel). 2021 Jul 15;14(7):680. doi: 10.3390/ph14070680.
引用本文的文献
1
Cytokines from Macrophages Activated by Spike S1 of SARS-CoV-2 Cause eNOS/Arginase Imbalance in Endothelial Cells.由新冠病毒刺突蛋白S1激活的巨噬细胞产生的细胞因子导致内皮细胞中eNOS/精氨酸酶失衡。
Int J Mol Sci. 2025 Jun 19;26(12):5916. doi: 10.3390/ijms26125916.
2
Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis.巴瑞替尼治疗重症 COVID-19 患者的疗效和安全性：系统评价和荟萃分析。
Medicine (Baltimore). 2023 Dec 1;102(48):e36313. doi: 10.1097/MD.0000000000036313.
3
Plant-Derived Epi-Nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents.植物源表生营养物作为广谱抗病毒药物的潜力
Nutrients. 2023 Nov 8;15(22):4719. doi: 10.3390/nu15224719.
4
Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.巴瑞替尼和托珠单抗治疗新冠住院患者的疗效与安全性：一项基于系统评价和荟萃分析的比较
Front Pharmacol. 2022 Oct 14;13:1004308. doi: 10.3389/fphar.2022.1004308. eCollection 2022.
5
The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro.JAK1/2抑制剂巴瑞替尼减轻体外刺突诱导的免疫细胞和内皮细胞炎症反应。
Biomedicines. 2022 Sep 19;10(9):2324. doi: 10.3390/biomedicines10092324.
6
Immunomodulatory therapies for COVID-19.用于治疗新冠肺炎的免疫调节疗法。
Front Med (Lausanne). 2022 Aug 3;9:921452. doi: 10.3389/fmed.2022.921452. eCollection 2022.
本文引用的文献
1
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.巴瑞替尼用于住院COVID-19患者：随机对照试验的荟萃分析
EClinicalMedicine. 2022 Jul;49:101489. doi: 10.1016/j.eclinm.2022.101489. Epub 2022 Jun 3.
2
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性（COV-BARRIER）：一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
3
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
4
SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.SARS-CoV-2 通过网格蛋白介导的内吞作用感染细胞。
J Biol Chem. 2021 Jan-Jun;296:100306. doi: 10.1016/j.jbc.2021.100306. Epub 2021 Jan 19.
5
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
6
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
7
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.细胞因子风暴的特征反映了 COVID-19 中的过度炎症性内皮功能障碍。
J Allergy Clin Immunol. 2021 Jan;147(1):107-111. doi: 10.1016/j.jaci.2020.08.031. Epub 2020 Sep 10.
8
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
9
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
10
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
Zotero 插件